CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc.

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

IPO Year: 2021

Exchange: NASDAQ

Website: cogrx.com

Recent Analyst Ratings for Cognition Therapeutics Inc.

Date	Price Target	Rating	Analyst
12/19/2024	$1.00 → $1.50	Neutral → Buy	B. Riley Securities
7/30/2024		Overweight → Neutral	Cantor Fitzgerald
11/3/2021	$27.00	Buy	B. Riley Securities
11/3/2021	$22.00	Outperform	Oppenheimer

See more ratings

Cognition Therapeutics Inc. Leadership Updates

Live Leadership Updates

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements. "John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. We look forward to leveraging his skills, his relationships on Wall Street, and his strategic insights as we move forward together as a company," said Lisa Ricciard
5/1/23 7:30:44 AM ET
$CGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®. "We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer's disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer's disease and dry age-related macular degeneration in the near-term,
10/11/22 8:00:00 AM ET
$CGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone
PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the "Company" or "Cognition"), today announced the addition of Ellen B. Richstone to the company's board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition's board, having served as chief financial officer and treasurer for Fortune 500 companies, and as a board member for c
11/3/21 8:00:00 AM ET
$CGTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Cognition Therapeutics Inc.

Recent Analyst Ratings for Cognition Therapeutics Inc.

Cognition Therapeutics Inc. SEC Filings

Cognition Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Cognition Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Cognition Therapeutics Inc.

Cognition Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Cognition Therapeutics Inc.

SEC Form DEF 14A filed by Cognition Therapeutics Inc.

SEC Form 424B5 filed by Cognition Therapeutics Inc.

SEC Form S-8 filed by Cognition Therapeutics Inc.

Cognition Therapeutics Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO & President Ricciardi Lisa covered exercise/tax liability with 28,960 shares, was granted 631,300 shares and bought $30,001 worth of shares (38,851 units at $0.77), increasing direct ownership by 207% to 893,685 units (SEC Form 4)

Ricciardi Lisa bought $9,975 worth of shares (5,700 units at $1.75), increasing direct ownership by 2% to 291,345 units (SEC Form 4)

Cognition Therapeutics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cognition Therapeutics upgraded by B. Riley Securities with a new price target

Cognition Therapeutics downgraded by Cantor Fitzgerald

B. Riley Securities initiated coverage on Cognition Therapeutics with a new price target

Oppenheimer initiated coverage on Cognition Therapeutics with a new price target

Cognition Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Khattar Jack A. was granted 34,000 shares, increasing direct ownership by 234% to 48,500 units (SEC Form 4)

Director Wallace Peggy was granted 34,000 shares, increasing direct ownership by 65% to 86,461 units (SEC Form 4)

Director Richstone Ellen B was granted 34,000 shares, increasing direct ownership by 139% to 58,500 units (SEC Form 4)

Director Monia Brett P was granted 34,000 shares, increasing direct ownership by 234% to 48,500 units (SEC Form 4)

Director Kreis Leslie W. was granted 34,000 shares (SEC Form 4)

Director Fletcher Aaron G.L. was granted 34,000 shares (SEC Form 4)

Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 9,692 shares, decreasing direct ownership by 2% to 404,710 units (SEC Form 4)

CEO & President Ricciardi Lisa covered exercise/tax liability with 6,619 shares, decreasing direct ownership by 0.74% to 887,066 units (SEC Form 4)

Chief Medical Officer Caggiano Anthony covered exercise/tax liability with 5,296 shares, decreasing direct ownership by 1% to 418,554 units (SEC Form 4)

Chief Financial Officer Doyle John Brendan covered exercise/tax liability with 1,723 shares, decreasing direct ownership by 0.41% to 414,402 units (SEC Form 4)

Cognition Therapeutics Inc. Leadership Updates

Live Leadership Updates

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone